Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Enfuvirtide (Fuzeon) Peptide
First-in-class HIV fusion inhibitor peptide.
What is Enfuvirtide (Fuzeon)?
Enfuvirtide (Fuzeon) is a fusion inhibitor · antiviral peptide studied for treatment-experienced hiv-1 infection. Below is an educational overview of Enfuvirtide (Fuzeon) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Fuzeon
HIV-1 infection in treatment-experienced adults/children, used with other antiretrovirals.
A twice-daily injection that blocks HIV from fusing into and infecting human cells.
- •Injection-site reactions (nearly universal)
- •Diarrhea
- •Nausea
- •Fatigue
- •Pneumonia (higher risk)
- •Hypersensitivity reactions on re-exposure
- •Previous hypersensitivity to enfuvirtide
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Enfuvirtide (Fuzeon) Mechanism of Action
36-amino-acid peptide that binds the gp41 subunit of HIV-1 envelope, blocking the conformational change required for viral-host membrane fusion and cell entry.
Enfuvirtide (Fuzeon) Research Areas & Benefits
Enfuvirtide (Fuzeon) Dosage & Common Research Protocols
90 mg SC twice daily as part of combination ART.
Protocols summarized for educational reference from published research. Not dosing guidance.
Enfuvirtide (Fuzeon) Studies & Cited Research
TORO 1 & 2 trials
Added enfuvirtide significantly reduced viral load in treatment-experienced patients.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Enfuvirtide (Fuzeon) Side Effects & Safety Considerations
- •FDA-approved.
- •Injection-site reactions nearly universal.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.